Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M, García-Conde J, Sanz G, Arranz R, Bernal MT, de la Serna J, Díez JL, Moraleda JM, Rubió-Félix D, Xicoy B, Martínez C, Mateos MV, Sierra J. Alvarez I, et al. Among authors: canales m. Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83. doi: 10.1016/j.bbmt.2005.09.009. Biol Blood Marrow Transplant. 2006. PMID: 16443515 Free article. Clinical Trial.
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S; UK and Spanish Collaborative Groups. Peggs KS, et al. Among authors: canales m. Br J Haematol. 2007 Oct;139(1):70-80. doi: 10.1111/j.1365-2141.2007.06759.x. Br J Haematol. 2007. PMID: 17854309 Free article. Clinical Trial.
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Garcia-Sanz R, et al. Among authors: canales m. Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009. Ann Oncol. 2019. PMID: 30657848 Free article. Clinical Trial.
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo AM, Valcárcel D, González-Rodríguez AP, Suárez-Lledó M, Bello JL, Canales M, Gayoso J, Colorado M, Jarque I, Del Campo R, Arranz R, Terol MJ, Rifón JJ, Rodríguez MJ, Ramírez MJ, Castro N, Sánchez A, López-Jiménez J, Montes-Moreno S, Briones J, López A, Palomera L, López-Guillermo A, Caballero D, Martín A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO). Redondo AM, et al. Among authors: canales m. Br J Haematol. 2019 Mar;184(5):797-807. doi: 10.1111/bjh.15713. Epub 2018 Dec 12. Br J Haematol. 2019. PMID: 30548583 Free article. Clinical Trial.
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO). Briones J, et al. Among authors: canales ma. Haematologica. 2014 Jul;99(7):e126. doi: 10.3324/haematol.2014.108308. Haematologica. 2014. PMID: 24986878 Free PMC article. No abstract available.
A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.
Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA, García JF; Spanish Hodgkin Lymphoma Study Group. Sánchez-Espiridión B, et al. Among authors: canales m. Blood. 2010 Aug 26;116(8):e12-7. doi: 10.1182/blood-2010-02-270009. Epub 2010 May 17. Blood. 2010. PMID: 20479282 Free article. Clinical Trial.
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J. Tomás JF, et al. Among authors: canales m. Leuk Lymphoma. 2011 Mar;52(3):409-16. doi: 10.3109/10428194.2010.543717. Epub 2011 Jan 28. Leuk Lymphoma. 2011. PMID: 21275633 Clinical Trial.
Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO. Briones J, et al. Among authors: canales ma. Haematologica. 2014 Mar;99(3):505-10. doi: 10.3324/haematol.2013.093450. Epub 2013 Oct 25. Haematologica. 2014. PMID: 24162789 Free PMC article. Clinical Trial.
342 results